Recent Updates
Recently added Catalysts
SYRE Positive Sentiment

Spyre Therapeutics to Participate in Upcoming Investor Conferences

Key Takeaway: Spyre Therapeutics announced its participation in several upcoming investor conferences in November and December 2026. Key events include the UBS Global Biopharma Conference and the Jefferies Global Healthcare Conference, both in London. Management will also hold one-on-one meetings with investors during these events.

Market Sentiment Analysis

POSITIVE FACTORS

  • Spyre is participating in multiple investor conferences.
  • Management will host one-on-one investor meetings.
  • Spyre aims to elevate standards in immunology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+64%
120-day peak, hindsight
Typical move
9%
average across 9 past catalysts
Cash runway
~41 mo
Low dilution risk
Lead asset
SPY001
Phase 2 · Ulcerative Colitis

Full Press Release Details

WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences in November and December:

Event: UBS Global Biopharma Conference – London Date: Monday, November 16, 2026 Fireside Time: 1:20 pm GMT

Event: Jefferies Global Healthcare Conference – London Date: Tuesday, November 17, 2026 Fireside Time: 3:00 pm GMT

Event: 9th Annual Evercore Healthcare Conference - Miami Date: Tuesday, December 1, 2026 Fireside Time: 3:00 pm ET

Event: Citi’s 2026 Global Healthcare Conference - Miami Date: Wednesday, December 2, 2026 Fireside Time: 9:40 am ET

Members of the Spyre management team will also host one-on-one investor meetings during the conferences.
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.
For more information, visit Spyre's website at www.spyre.com.

For Investors: Eric McIntyre, Spyre Therapeutics SVP of Finance and Investor Relations Eric.mcintyre@spyre.com

Frequently Asked Questions

What conferences will Spyre Therapeutics attend?

Spyre will attend the UBS and Jefferies conferences in London.

When is the UBS Global Biopharma Conference?

The UBS conference is on November 16, 2026.

Will there be one-on-one meetings with investors?

Yes, management will host one-on-one investor meetings.

Where can I find the conference webcasts?

Live webcasts will be available on Spyre's investor events website.

Last updated: Nov 10, 2026